

YEAR END REPORT

1/1-31/12 2019



WE WILL BE READY FOR INDITREAT LAUNCH IN SECOND HALF OF 2020

"2019 has been an exciting transition year for 2cureX – from an R&D company with our IndiTreat® test participating in clinical trials to a commercial company. We have been focusing on go to market strategies in 2019 and we are now ready to exploit the attractive market trends towards Functional Precision Medicine in the second half of 2020. The recognition that personalized treatment of cancer patients requires a functional test like IndiTreat® is fundamental to our business" says Ole Thastrup, CEO of 2cureX.

(KSEK) if not stated otherwise	Q4 2019 1/10-31/12	Q4 2018 1/10-31/12	2019 1/1-31/12	2018 1/1-31/12
Net sales	0	0	0	0
Profit before tax	-2 740	-1 783	-9 411	-8 542
Earnings per share*	-0,17	-0,05	-0,68	-0,70
Equity ratio**	74%	57%	74%	57%
Cash and bank	33 720	20 063	33 720	20 063
Average number of shares	12 420 000	10 350 000	11 609 014	10 350 000
No. of shares by the end of the period	12 420 000	10 350 000	12 240 000	10 350 000

***Earnings per share:** Profit for the period divided by the average number of shares.

****Equity ratio:** Shareholder's equity divided by total capital.

Significant events in Q4 2019:

- **Commercial agreement:** 2cureX and Docrates, the largest private cancer hospital in the Nordics, signed a commercial agreement (PR, 8 October 2019).
- **Patent protection:** 2cureX secured patent protection in the US (PR, 6 November 2019) and Hong Kong (PR, 15 October 2019).
- **R&D:** Progression in the IndiTreat® immuno-oncology assay development was presented at the ESMO Immuno-Oncology Congress in Geneva (PR, 13 December 2019).
- **Awareness:** The IndiTreat.com website dedicated to patients and doctors was launched (News, 10 December 2019).

CONTACT: Ole Thastrup CEO / Fruebjergvej 3 / 2100 Copenhagen / Danmark / ot@2curex.com / www.2curex.com

SIGNIFICANT EVENTS THROUGHOUT 2019:

Trials and clinical evidence on track:

- Interim data from 2cureX's colorectal cancer trial showed that both clinical and technical endpoints were met (PR, 20 February 2019).
- An additional clinical trial was launched in Preventive Cancer Medicine (PR, 12 March 2019).

Securing the IndiTreat® test:

- The core IndiTreat patent was granted in the US (PR, 6 November 2019) and in Hong Kong (15 October 2019).

Partner agreements signed:

- 2cureX and Docrates, the largest cancer hospital in the Nordics, signed an Early Access Agreement (PR, 8 October 2019).
- 2cureX and the US-based biotech company, Gibson Oncology LLC, signed an agreement on stratification of patients in a clinical trial for a new drug in colorectal cancer (PR, 4 April 2019).

Financials strengthened:

- 2cureX successfully completed a Right Issue where SEK 24,7 million was raised with an oversubscription of 241 percent (PR, 28 May 2019).

Management team expanded:

- Strengthening of 2cureX Management Team with CFO Carit J. Andersen (PR, 16 January 2019) and CMO Henrik Harling (PR, 20 June 2019).

SIGNIFICANT EVENTS AFTER THE REPORTING PERIOD:

- **Trials:** 2cureX's clinical trial in colorectal cancer has successfully enrolled 75% of the patients needed to finalize the trial (PR, 30 January 2020).
- **Patent protection:** 2cureX obtained patent protection in Australia (PR, 6 January 2020)

2020 EXPECTATIONS:

The results of the first interventional colorectal cancer trial where treatment is guided by the IndiTreat test are expected in second half of 2020. In parallel, the general launch of IndiTreat will be commenced. Sales and marketing resources will be allocated throughout the year including additional agreements with new partners and specialized consultants.

For more information please contact:

Ole Thastrup, CEO
Mobile: +45 22 11 53 99
Mail: ot@2curex.com

Next Investor presentation:

10 March 2020 at Redeye's "Fight Cancer Seminar" in Stockholm
Registration: <https://www.redeye.se/events#/event/585001>

2cureX and IndiTreat are registered trademarks of 2cureX AB

INDITREAT HAS BEEN CONSOLIDATED IN 2019

2019 has been a very busy year for 2cureX. As planned, we have strengthened the IndiTreat technology and transformed the focus of 2cureX from R&D and clinical trials to commercialization. Thus, we have the tools ready for a successful 2020 commercial launch of IndiTreat.

Launch of IndiTreat test has been prepared since the establishment of IndiTreat Business Unit in January 2018 headed by Chief Business Officer, Maarten van der Linden. We are confident that 2cureX is ready for commercialization of IndiTreat in second half of 2020. We have CE-IVD approval, clinical validation of IndiTreat is constantly expanding, and organisational build-up is finalized in both Denmark and Germany. Establishment of commercial partnerships is ongoing and IndiTreat is successfully branded as a unique Functional Precision Medicine test.

2cureX is ready for market launch of IndiTreat in second half of 2020.

Clinical validation on track

IndiTreat is currently being clinically validated for treatment guidance in three major cancers: colorectal, ovarian and pancreatic cancer. Colorectal cancer will be the primary indication when IndiTreat is launched.

In the beginning of 2019, very positive interim data from our interventional trial in metastatic colorectal cancer were presented at the ESMO Congress in Barcelona. In January 2020 we announced that 75% of the patients needed to finalise the trial, had been enrolled and treated in accordance with the IndiTreat test results.

The Primary Investigator at Vejle University Hospital will publish the final results of the study late 2020 when the last patient included has had the required follow-up examination eight weeks after initiation of IndiTreat-guided treatment.

Alongside this study, we will continue to run new clinical studies. These are not a prerequisite for commercialisation, but they will explore and strengthen the utility of the IndiTreat test.

Functional Precision Medicine is gaining momentum

Since the concept of a personalized cancer treatment was fostered more than 20 years ago, Precision Medicine has been synonymous with treatment based on results of genetic testing. However, there is a growing recognition that genetic testing per se is not sufficiently effective*. It is necessary to add a functional analysis predicting which drugs and drug combinations are effective against a patient's cancer cells irrespective of genetic mutations. This is exactly the principle of the functional IndiTreat test.

**At the end of 2019 ESMO (European Society for Medical Oncology) concluded that no more than 0,8 -3% of cancer patients respond to drugs that were selected based on genetic analysis.*

Partnering is essential for our success

2cureX has established clinical agreements with major cancer centers in Denmark, Germany, Sweden and United Kingdom. In 2019 we launched an Early Access program (previously called pre-launch) to define the IndiTreat offering, logistics and other details related to customers in markets where 2cureX was not involved in clinical trials. In 2019 2cureX signed such agreement with Docrates covering the Finish and Baltic market.

2cureX's vision of improving treatment efficiency for cancer patients requires a close dialogue with patient organizations devoted to the major cancers. This has also been a prioritized focus area in 2019.

Beyond being a Functional Precision Medicine tool, IndiTreat has a great potential to guide patient inclusion in clinical trials for new drugs. In 2019, 2cureX established its first patient stratification agreement with the US-based biotech company, Gibson Oncology.

2020 in the sign of commercialisation

The main objective for 2020 is launch of IndiTreat for colorectal cancer patients. To meet this goal, we are in active dialogue with the following customer groups:

- a) oncologists at public and private hospitals,
- b) commercial Labs that provide services to hospitals, and
- c) distributors that deliver tests to hospitals.

We intend to strengthen our sales and marketing organization with new appointments as well as entering into new partnerships and specialized consultant agreements in dedicated markets.

2cureX will actively support and exploit **Functional Precision Medicine** as an essential component of Precision Medicine.

We value **quality, transparency and trust** towards both partners and shareholders.



“Thank you to our shareholders and partners for your support and trust in 2019. I look forward to move 2cureX to the next level together with the dedicated 2cureX-team and partners”

February 28. 2020, Ole Thastrup, CEO, 2cureX

2CUREX IN BRIEF

2cureX is a MedTech company that has developed the IndiTreat® test for individualizing the treatment of cancer patients. 2cureX strives to establish IndiTreat as a global standard for Functional Precision Medicine.

2cureX was founded in 2006 as a spin-out from the Carlsberg Research Centre in Copenhagen, with the vision of improving treatment efficiency for cancer patients. From its inception, 2cureX has been closely related to major cancer hospitals in the Nordic countries, Germany and the UK.

The key product of 2cureX is the IndiTreat test that allows the physician to identify a medical treatment that is effective for a particular patient. At the same time the test will reveal drugs to which the patient is resistant. IndiTreat is patent protected in major markets. Additionally, IndiTreat has received CE-IVD marking which allows commercialization in the European market.

IndiTreat®

The IndiTreat test is performed on thousands of tumor copies established from a small tissue sample (biopsy) from a patient's tumor. These copies (named tumoroids) have similar properties as the original tumor and can be grown outside the patient's body. The tumoroids are exposed to available anticancer drugs dedicated to the specific cancer the patient suffers from or anticancer drugs registered for other cancers. The treatment identified that kills the patient's tumor can be provided to the patient immediately after testing.

Clinical studies

2cureX conducts multiple clinical studies at clinical centers in Germany, UK and Denmark. The studies are carried out primarily in colorectal cancer but also in pancreatic- and ovarian cancer. 2cureX and its clinical partners have provided clinical evidence that IndiTreat improves patient outcome. The number of clinical studies are constantly expanding on the request from partner hospitals. This implies that additional clinical evidence emerges "as we go".

The clinical trials will continuously explore and strengthen the potential of the IndiTreat test and are a vital part of our product lifecycle development program to ensure a long-term competitive advantage.

2cureX has office in Copenhagen and a subsidiary in Hamburg. 2cureX AB is listed at Nasdaq First North Growth Market (NASDAQ: 2CUREX).

For more information: www.2curex.com



**CLINICAL TRIALS GO
HAND-IN-HAND WITH
COMMERCIALIZATION**

COMMERCIALIZATION STRATEGY AND MARKET POTENTIAL

A Large and growing market opens for strong positioning of IndiTreat.

Large and growing market potential

2cureX is operating in three major cancer entities: colorectal, ovarian and pancreatic cancer. The number of new cancer patients each year, suitable for medical treatment, amounts to more than 400.000, thus eligible to IndiTreat testing. We estimate that the size of the present IndiTreat testing market in Europe is approx. 12 billion SEK.

The cancer incidence is increasing as the population grows older. The potential of IndiTreat will increase even further as cancer patients live longer due to improved treatment. Usually treatment includes several lines of chemotherapy to which the patients over time become resistant. Particularly in ovarian- and colorectal cancer the belief is that the disease can be turned into a chronic situation, which requires changing treatments as resistance occurs.


IndiTreat can be an important tool for identifying an effective treatment up-front, and later when resistance occurs.

We are eager to capture market share in this growing and important market.

The commercialization of IndiTreat will follow two tracks

The commercialisation tracks for IndiTreat are:

- a) Individualization of cancer treatment
- b) Patient stratification in clinical drug trials.



Individualization of cancer treatment

IndiTreat will primarily be offered to cancer hospitals and patients as a fee for service. Each patient's tumor will be tested for sensitivity towards a large panel of approved drugs and drug combinations. Immediately after testing the hospital can offer the patient the identified treatment.

The business model for Individualized cancer treatment follows a classical pay per patient structure; a model the hospital system is used to handle. The price per test is linked to volume of tests conducted.


Patient stratification in clinical drug trials

In the second element of 2cureX's commercialization, "Patient stratification", we offer the IndiTreat test to biotech and pharma companies to select the patients that are most likely to respond to the drug candidate of their clinical trials. IndiTreat-based selection of responding patients will increase the significance of the clinical trial drug response, lower the number of patients needed and thereby lower costs. 2cureX offers patient stratification in upside-based agreements (royalties and milestone payments).

Status of commercialization

In 2019 2cureX started an Early Access program with the purpose of defining the offering, logistics and other details associated with the test performance and transfer of results, for different customer profiles. We have established agreements with hospitals/partners in European markets where we presently do not conduct clinical studies. It is essential that all processes are running smoothly in all European markets.

EARLY ACCESS ACTIVITIES



In parallel with the Early Access activities we are in commercial discussions with potential customers, that are to support the full market launch in second half of 2020, in following categories:

- Oncologists at public and private hospitals
- Commercial Labs that provide test services to Cancer departments
- IVD Distributors that distribute IVD tests to Cancer departments

"In the second half of 2020 we begin to reap the rewards of our investment in commercialization and help the actual "customers" – the patients"

Maarten van der Linden, CBO, 2cureX




FUNCTIONAL PRECISION MEDICINE WILL MAKE PERSONALIZED CANCER TREATMENT A REALITY

The purpose of Personalized Medicine or Precision Medicine within medical cancer treatment is to select an effective treatment for each patient to improve survival and to avoid side effects of ineffective treatment.

Precision Medicine has become synonymous with genetic testing of a patient's tumor to guide treatment – so called **Genomic Precision Medicine**. The starting point is to undertake genetic testing of tumors to find mutations that can be attacked with drugs which then kill the cancer cells. However, our knowledge of carcinogenic mutations and how the process from mutation to cancer development occurs is very incomplete. Despite of massive research efforts and huge financial support from both public and private sources, after 20 years Genomic Precision Medicine has only led to effective cancer treatment for very few patients.

The major oncology society in Europe, ESMO (European Society for Medical Oncology) published in 2019 results from 11 clinical trials including more than 13.000 patients showing that only 0,8 – 3% of the cancer patients responded to drugs selected on the basis of genetic analysis.



MOLECULAR TUMOUR BOARDS AND PRECISION CANCER MEDICINE
– Dirk Arnold & Benedikt Westphalen

ESMO 2019

Functional Precision Medicine arose out of recognition of the shortcomings of Genomic Precision Medicine. There is a tremendous utility in exposing patient tumor cells directly to the drugs that could be used to treat them in order to find the best match between a tumor and a drug. Prominent cancer institutions are now moving towards Functional Precision Medicine in the realization that Precision Medicine will only become a reality if Functional Profiling of a tumor is undertaken in parallel with Genomic Profiling.

2cureX has since 2006 pioneered Functional Precision Medicine. 2cureX's cutting-edge functional technology, IndiTreat®, matching cancer patient with effective drug, is positioned to become a routine tool in the care of cancer patients. In clinical studies IndiTreat® has already shown its ability to improve treatment outcome in colorectal cancer. A thorough information about the IndiTreat® test can be obtained from www.inditreat.com

“Bringing IndiTreat to the market shall very likely improve the outcome for cancer patients and reduce costs due to ineffective treatment. The perspectives are indeed impressive”

Henrik Harling, CMO, 2cureX



DEVELOPMENT DURING THE FINANCIAL YEAR AND THE FOURTH QUARTER OF 2019, IN FIGURES

*Numbers within parentheses refer to the corresponding period in the preceding year.
For additional information about 2cureX's financial position and development, please
refer to the Company's website (www.2cureX.com).*

Net sales and operating income

Net sales amounted to KSEK 0 (0) in 2019 and KSEK 0 (0) in the fourth quarter of 2019. The Company had no sales during the quarter; all income is attributable to various contributions and public grants.

Financial development

The loss amounted to KSEK -7,933 (-7,264) for 2019 and KSEK -2,138 (-505) for the fourth quarter of 2019. The result for the period has been impacted by the key element of the operations, namely the conduct of clinical trials initiated to validate the IndiTreat® technology. A significant part of the clinical operations are funded by an EU grant called MicroCaT, recognized as Other operating income in the income statement.

Cash flow

The Group's cash and cash equivalents amounted to KSEK 33,720 (20,063) as of 31 December 2019. Cash flow amounted to KSEK 13,961 (-48) in 2019 and KSEK -3,789 (-3,774) in the fourth quarter of 2019. Cash flow from operating activities amounted to KSEK -7,864 (1,150) in 2019 and KSEK -3,992 (-3,769) in the fourth quarter of 2019. The monthly burn rate is approximately MSEK -1.5, which is in line with expectations.

Equity ratio

The Group's Equity ratio as of 31 December 2019 amounted to 74 percent (57).

The share

There is one class of shares in 2cureX AB. The Company's share is listed on Nasdaq First North Growth Market under the ticker "2CUREX". As of 31 December 2019, the number of shares amounted to 12,420,000 (10,350,000). The average number of shares during the fourth quarter of 2019 amounted to 12,420,000 (10,350,000).

Employee stock options

The Annual General Meeting on 28 May 2018 resolved to establish a Series 2018/2020 and a Series 2018/2021 warrant programme for the Group's employees and key personnel. The employee warrants, totalling 360,000 warrants, carry the right to subscribe for newly issued shares in 2cureX AB in the period 28 May 2020 to 28 September 2020 and in the period 1 April 2021 to 28 September 2021, respectively. Each subscription warrant entitles the holder to subscribe for 1 share, at a subscription price of SEK 8.86 per share. Upon full exercise of the issued warrants, the share capital would increase by SEK 36,000. The employee warrants will be subject to the usual conversion terms in connection with new share issues, etc. The Group's result for 2019 has been impacted by costs to the amount of KSEK 335 in the form of personnel costs.

Proposed appropriations of 2cureX AB's result

The Board of Directors and the Chief Executive Officer propose that no dividend be paid for the financial year 1 January 2019 to 31 December 2019.

Annual General Meeting and availability of the annual report

The Annual General Meeting will be held in Malmö on 28 May 2020. The annual report will be available for download on the Company's website (www.2cureX.com) three weeks prior to the AGM, at the latest.

Policies for the preparation of the year-end report

2cureX AB applies the Swedish Annual Accounts Act as well as the Swedish Accounting Standards Board BFNAR 2012:1 annual report and consolidated (K3) in the preparation of its financial reports.

Auditors' review

This year-end report has not been reviewed by the Company's auditors.

Financial calendar

The Company prepares and publishes a financial report at the end of each quarter. Upcoming reports are planned to be released as follows:

- | | |
|----------------------------|------------|
| • Interim report 1, 2020 | 28/5-2020 |
| • Half-yearly report, 2020 | 27/8-2020 |
| • Interim report 3, 2020 | 26/11-2020 |
| • Year-end report, 2020 | 28/2-2021 |



DELIVERY OF YEAR END REPORT

Landskrona, February 28, 2020
2cureX AB

BOARD OF DIRECTORS

Povl-André Bendz

Chairman of the Board

Jørgen Drejer

Board

Camilla Huse Bondesson

Board

Timm Jessen

Board

Ole Thastrup

Board and CEO

Certified Adviser

Svensk Kapitalmarknadsgranskning AB

Telefon: **+46 70 755 95 51**

E-post: **ca@skmg.se**

FINANCIAL OVERVIEW

SUMMARY OF INCOME STATEMENT – THE GROUP

(KSEK)	Q4 2019 1/10-31/12	Q4 2018 1/10-31/12	2019 1/1-31/12	2018 1/1-31/12
Operating income				
Net sales	0	0	0	0
Other operating income	4 785	3 242	11 982	7 675
Total operating income	4 785	3 242	11 982	7 675
Operating expenses				
Other external expenses	-4 028	-1 826	-9 376	-6 838
Personnel costs	-2 625	-2 926	-10 919	-8 842
Depreciation of tangible fixed assets	-114	-167	-436	-431
Total operating expenses	-6 767	-4 919	-20 731	-16 111
Operating profit	-1 982	-1 677	-8 749	-8 436
Financial posts	-758	-106	-662	-106
Profit before tax	-2 740	-1 783	-9 411	-8 542
Tax 1)	602	1 278	1 478	1 278
The result of the period	-2 138	-505	-7 933	-7 264
Earnings per share (SEK)	-0,17	-0,05	-0,68	-0,70
Average number of shares	12 420 000	10 350 000	11 609 014	10 350 000
No. of shares at the end of the period	12 420 000	10 350 000	12 420 000	10 350 000

1) This post refers to tax relief in subsidiaries regarding R&D work.

SUMMARY OF BALANCE SHEET – THE GROUP

(KSEK)	31/12-2019	31/12-2018
Assets		
Fixed assets		
Tangible fixed assets	1 015	1 384
Total fixed assets	1 015	1 384
Current assets		
Receivables	3 106	2 579
Cash and bank balances	33 720	20 063
Total current assets	36 826	22 642
Total assets	37 841	24 026
Equity and liabilities		
Equity		
Share capital	1 242	1 035
Other contributed capital	38 023	16 385
Other equity	-3 256	3 465
The result of the period	-7 933	-7 264
Total equity	28 076	13 621
Current liabilities		
Short-term liabilities 2)	9 765	10 405
Total short-term liabilities	9 765	10 405
Total equity and liabilities	37 841	24 026

2) This post includes prepaid contributions from the EU amounting to 6 074 KSEK (9 354 KSEK).

SUMMARY OF CASH FLOW – THE GROUP

(KSEK)	Q4 2019 1/10-31/12	Q4 2018 1/10-31/12	2019 1/1-31/12	2018 1/1-31/12
Cash flow from operating activities	-3 769	-3 150	-7 864	1 150
Cash flow from investment activities	-20	-624	-20	-1 198
Cash flow from financing activities	0	0	21 845	0
Cash flow for the period	-3 789	-3 774	13 961	-48
Cash and cash equivalents at the beginning of the period	38 655	23 848	20 063	19 985
Exchange rate difference in cash and cash equivalents	-1 146	-11	-304	126
Cash and cash equivalents at the end of the period	33 720	20 063	33 720	20 063

CHANGE OF EQUITY – THE GROUP

1/1-2018 – 31/12-2018

(KSEK)	Share capital	Other contributed capital	Other equity	Result of the period	Total
At the beginning of the period (1/1-2018)	1 035	16 385	5 953	-3 136	20 237
Outline of previous year's results			-3 136	3 136	0
Issue of options			508		508
Translation difference			140		140
The result of the period				-7 264	-7 264
At the end of the period (31/12-2018)	1 035	16 385	3 465	-7 264	13 621

1/1-2019 – 31/12-2019

(KSEK)	Share capital	Other contributed capital	Other equity	Result of the period	Total
At the beginning of the period (1/1-2019)	1 035	16 385	3 465	-7 264	13 621
Outline of previous year's results			-7 264	7 264	0
Rights issue	207	24 529			24 736
Issue costs		-2 891			-2 891
Allocation of staff warrants			316		316
Translation difference			227		227
The result of the period				-7 933	-7 933
At the end of the period (31/12-2019)	1 242	38 023	-3 256	-7 933	28 076

SUMMARY OF INCOME STATEMENT – PARENT COMPANY

(KSEK)	Q4 2019 1/10-31/12	Q4 2018 1/10-31/12	2019 1/1-31/12	2018 1/1-31/12
Operating income				
Net sales	0	0	0	0
Total operating income	0	0	0	0
Operating expenses				
Other external expenses	-409	-496	-1 694	-1 519
Staff costs	-66	0	-265	0
Total operating expenses	-475	-496	-1 959	-1 519
Operating profit	-475	-496	-1 959	-1 519
Financial posts	338	-9 927	42	-9 927
Profit before tax	-137	-10 423	-1 917	-11 446
Tax	0	0	0	0
The result of the period	-137	-10 423	-1 917	-11 446

SUMMARY OF BALANCE SHEET – PARENT COMPANY

(KSEK)	31/12-2019	31/12-2018
Assets		
Fixed assets		
Financial assets	27 376	5 000
Total fixed assets	27 376	5 000
Current assets		
Receivables	298	584
Cash and bank balances	2 534	14 294
Total current assets	2 832	14 878
Total assets	30 208	19 878
Equity and liabilities		
Equity		
Share capital	1 242	1 035
Premium fund	42 223	20 585
Balanced result	-11 646	-516
The result of the period	-1 917	-11 446
Total equity	29 902	9 658
Current liabilities		
Current liabilities	306	10 220
Total short-term liabilities	306	10 220
Total equity and liabilities	30 208	19 878

CASH FLOW STATEMENT IN SUMMARY – PARENT COMPANY

(KSEK)	Q4 2019 1/10-31/12	Q4 2018 1/10-31/12	2019 1/1-31/12	2018 1/1-31/12
Cash flow from operating activities	-604	-464	-1 206	-2 540
Cash flow from investment activities	0	0	-32 399	0
Cash flow from financing activities	0	0	21 845	0
Cash flow for the period	-604	-464	-11 760	-2 540
Cash and cash equivalents at the beginning of the period	3 138	14 758	14 294	16 834
Cash and cash equivalents at the end of the period	2 534	14 294	2 534	14 294

CHANGE OF EQUITY – PARENT COMPANY

1/1-2018 – 31/12-2018

(KSEK)	Share capital	Other contributed capital	Other equity	Result of the period	Total
At the beginning of the period (1/1-2018)	1 035	20 585	0	-1 024	20 596
Outline of previous year's results			-1 024	1 024	0
Issue of options			508		508
The result of the period				-11 446	-11 446
At the end of the period (31/12-2018)	1 035	20 585	-516	-11 446	9 658

1/1-2019 – 31/12-2019

(KSEK)	Share capital	Other contributed capital	Other equity	Result of the period	Total
At the beginning of the period (1/1-2019)	1 035	20 585	-516	-11 446	9 658
Outline of previous year's results			-11 446	11 446	0
Rights issue	207	24 529			24 736
Issue costs		-2 891			-2 891
Allocation of staff warrants			316		316
The result of the period				-1 917	-1 917
At the end of the period (31/12-2019)	1 242	42 223	-11 646	-1 917	29 902

A woman with short blonde hair, wearing a light blue headband and a white bathrobe, is smiling and holding a white ceramic mug with gold polka dots. She is standing in front of white vertical blinds. The 2curex logo is in the top left corner.

2curex

2CUREX AB

Fruebjergvej 3
DK-2100 Copenhagen
Denmark
Phone: **+45 2211 5399**
E-mail: **info@2curex.com**

A large, stylized blue 'X' logo is positioned in the bottom right corner of the image.

– because cancer patients are individuals